Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Niacin71 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A01100 | 34869532 | Front Nutr | Clinical Relevance of Vitamins and Carotenoids With Liver Steatosis and Fibrosis Detected by Transient Elastography in Adults. | 2021 | Details |
| A03768 | 33870623 | Mol Nutr Food Res | Nicotinamide Protects Against Diet-Induced Body Weight Gain, Increases Energy Expenditure, and Induces White Adipose Tissue Beiging. | 2021 | Details |
| A05022 | 33408299 | J Toxicol Sci | Reduction of fatty liver in rats by nicotinamide via the regeneration of the methionine cycle and the inhibition of aldehyde oxidase. | 2021 | Details |
| A06028 | 33035588 | Life Sci | Nicotinamide and ascorbic acid nanoparticles against the hepatic insult induced in rats by high fat high fructose diet: A comparative study. | 2020 | Details |
| A07521 | 32460191 | Biomed Pharmacother | Sodium acetate-mediated inhibition of histone deacetylase alleviates hepatic lipid dysregulation and its accompanied injury in streptozotocin-nicotinamide-induced diabetic rats. | 2020 | Details |
| A07664 | 32404278 | Biochim Biophys Acta Mol Cell Biol Lipids | Niacin increases diet-induced hepatic steatosis in B6129 mice. | 2020 | Details |
| A07840 | 32337855 | Mol Syst Biol | The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non-alcoholic fatty liver disease. | 2020 | Details |
| A08277 | 32171275 | BMC Pediatr | Analysis of the dietary factors associated with suspected pediatric nonalcoholic fatty liver disease and potential liver fibrosis: Korean National Health and Nutrition Examination Survey 2014-2017. | 2020 | Details |
| A09148 | 31858105 | J Nutr | Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet. | 2020 | Details |
| A09528 | 31706905 | J Clin Lipidol | Niacin for treatment of nonalcoholic fatty liver disease (NAFLD): novel use for an old drug? | 2019 | Details |
| A09681 | 31650383 | Mol Biol Rep | High fructose-containing drinking water-induced steatohepatitis in rats is prevented by the nicotinamide-mediated modulation of redox homeostasis and NADPH-producing enzymes. | 2019 | Details |
| A10090 | 31491949 | Int J Mol Sci | Combined Treatment with L-Carnitine and Nicotinamide Riboside Improves Hepatic Metabolism and Attenuates Obesity and Liver Steatosis. | 2019 | Details |
| A10462 | 31326093 | Am J Med Sci | Association Between Index of Nutritional Quality and Nonalcoholic Fatty Liver Disease: The Role of Vitamin D and B Group. | 2019 | Details |
| A10785 | 31195117 | Biochim Biophys Acta Mol Basis Dis | Nicotinamide riboside, an NAD+ precursor, attenuates the development of liver fibrosis in a diet-induced mouse model of liver fibrosis. | 2019 | Details |
| A11828 | 30718741 | Sci Rep | Dietary Niacin Intake Predicts the Decrease of Liver Fat Content During a Lifestyle Intervention. | 2019 | Details |
| A12460 | 30446221 | Biochem Biophys Res Commun | Alleviation of fatty liver in a rat model by enhancing N1-methylnicotinamide bioavailability through aldehyde oxidase inhibition. | 2018 | Details |
| A14423 | 29413998 | Curr Opin Pharmacol | Lipid-lowering treatment in peripheral artery disease. | 2018 | Details |
| A15157 | 29069580 | Eur J Pharmacol | Nicotinamide prevents sweet beverage-induced hepatic steatosis in rats by regulating the G6PD, NADPH/NADP+ and GSH/GSSG ratios and reducing oxidative and inflammatory stress. | 2017 | Details |
| A15289 | 28985579 | Eur J Cancer | Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. | 2017 | Details |
| A16274 | 28473059 | Nutr Res | Nicotinamide protects hepatocytes against palmitate-induced lipotoxicity via SIRT1-dependent autophagy induction. | 2017 | Details |
| A16286 | 28471474 | J Cell Physiol | Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells. | 2017 | Details |
| A17623 | 27710158 | Postgrad Med | Hypertriglyceridemia: the importance of identifying patients at risk. | 2016 | Details |
| A19289 | 26648069 | Curr Drug Targets | Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib. | 2016 | Details |
| A19702 | 26404765 | Hepatology | Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice. | 2015 | Details |
| A20336 | 26024755 | Metabolism | Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease. | 2015 | Details |
| A20590 | 25869616 | J Endocrinol | 11β-HSD1 reduces metabolic efficacy and adiponectin synthesis in hypertrophic adipocytes. | 2015 | Details |
| A20816 | 25714891 | Braz J Med Biol Res | Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model. | 2015 | Details |
| A20836 | 25702656 | Tumori | Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib. | 2015 | Details |
| A21405 | 25346221 | J Biophotonics | Raman spectroscopy analysis of lipid droplets content, distribution and saturation level in Non-Alcoholic Fatty Liver Disease in mice. | 2014 | Details |
| A21505 | 25268068 | Am J Clin Oncol | Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System. | 2016 | Details |
| A21732 | 25083925 | Prog Lipid Res | Recent advances in pharmacotherapy for hypertriglyceridemia. | 2014 | Details |
| A22535 | 24484068 | Liver Int | Metabolomic tissue signature in human non-alcoholic fatty liver disease identifies protective candidate metabolites. | 2014 | Details |
| A22672 | 24373179 | Diabetes Obes Metab | APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome. | 2014 | Details |
| A22723 | 24356885 | Am J Physiol Gastrointest Liver Physiol | Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease. | 2013 | Details |
| A22931 | 24197250 | J Gastroenterol | Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis. | 2013 | Details |
| A23155 | 23998651 | Liver Int | Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat. | 2013 | Details |
| A23641 | 23603006 | Food Chem Toxicol | Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1. | 2013 | Details |
| A24359 | 22969777 | Cardiorenal Med | Relationship between Changes in Plasma Adiponectin Concentration and Insulin Sensitivity after Niacin Therapy. | 2012 | Details |
| A24485 | 22847887 | Liver Transpl | Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis. | 2012 | Details |
| A24543 | 22770622 | Expert Opin Pharmacother | The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges. | 2012 | Details |
| A24674 | 22617751 | Curr Opin Lipidol | Nonalcoholic fatty liver disease and lipids. | 2012 | Details |
| A25922 | 21325336 | Acta Biochim Biophys Sin (Shanghai) | PGC-1 coactivators in the control of energy metabolism. | 2011 | Details |
| A26328 | 20647417 | Ann Pharmacother | Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease. | 2010 | Details |
| A26706 | 19925500 | Aliment Pharmacol Ther | Review article: the management of hepatocellular carcinoma. | 2009 | Details |
| A28474 | 12879992 | Clin Liver Dis | Hepatotoxicity of hypolipidemic drugs. | 2003 | Details |
| A32619 | 27964898 | Clin Oncol (R Coll Radiol) | Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit. | 2016 | Details |
| A34254 | 23948302 | J Autoimmun | STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib. | 2013 | Details |
| A35508 | 20494888 | Orv Hetil | [Hepatocellular carcinoma: occurrence, risk factors, biomarkers]. | 2010 | Details |
| A38208 | 11897208 | Am J Cardiol | Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. | 2002 | Details |
| A40857 | 6572892 | Postgrad Med | Gemfibrozil in combination with other drugs for severe hyperlipidemia. Preliminary study comprising four cases. | 1983 | Details |
| A44942 | 26661503 | Hepatology | Therapeutic potential of nicotinamide adenine dinucleotide for nonalcoholic fatty liver disease. | 2016 | Details |
| A45037 | 26352206 | Biochim Biophys Acta | Nicotinamide ameliorates palmitate-induced ER stress in hepatocytes via cAMP/PKA/CREB pathway-dependent Sirt1 upregulation. | 2015 | Details |
| A45235 | 25565897 | HIV AIDS (Auckl) | Managing dyslipidemia in HIV/AIDS patients: challenges and solutions. | 2014 | Details |
| A45294 | 25350520 | Horm Metab Res | Nonalcoholic Fatty liver disease and hyperuricemia: a close relation with hepatic insulin resistance after nicotinic Acid treatment? | 2014 | Details |
| A46209 | 20371660 | J Clin Endocrinol Metab | Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. | 2010 | Details |
| A46545 | 17723922 | Clin Liver Dis | Lipid-lowering agents that cause drug-induced hepatotoxicity. | 2007 | Details |
| A46734 | 16098839 | Am J Cardiol | Management of dyslipidemia in patients with complicated metabolic syndrome. | 2005 | Details |
| A46808 | 15151470 | Expert Rev Cardiovasc Ther | Treatment of metabolic syndrome. | 2004 | Details |
| A47917 | 29404461 | Hepatol Commun | CAT-2003: A novel sterol regulatory element-binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3-Leiden mice. | 2017 | Details |
| A48054 | 25501753 | J UOEH | New therapeutic strategy for hepatocellular carcinoma by molecular targeting agents via inhibition of cellular stress defense mechanisms. | 2014 | Details |
| A48606 | 33193106 | Front Endocrinol (Lausanne) | A Comprehensive Update on the Chylomicronemia Syndrome. | 2020 | Details |
| A48774 | 29175240 | J Hepatol | Reply to: "Energy drinks and adolescents - A hepatic health hazard?" | 2017 | Details |
| A48980 | 22419002 | Minerva Gastroenterol Dietol | Advanced HCC: emerging molecular therapies. | 2012 | Details |
| A52070 | 31676443 | Biochim Biophys Acta Mol Cell Biol Lipids | Increased fatty acid oxidation and mitochondrial proliferation in liver are associated with increased plasma kynurenine metabolites and nicotinamide levels in normolipidemic and carnitine-depleted rats. | 2019 | Details |
| A52263 | 29514072 | Cell Metab | Nicotinamide Improves Aspects of Healthspan, but Not Lifespan, in Mice. | 2018 | Details |
| A52466 | 26742069 | Nutrients | Peroxisome Proliferator-Activated Receptor Activation is Associated with Altered Plasma One-Carbon Metabolites and B-Vitamin Status in Rats. | 2016 | Details |
| A52694 | 23431266 | PLoS Biol | Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass. | 2013 | Details |
| A52783 | 22005032 | Biochim Biophys Acta | Hypertriglyceridemia secondary to obesity and diabetes. | 2011 | Details |
| A52960 | 18786125 | Am J Gastroenterol | The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis. | 2008 | Details |
| A53089 | 15166810 | Curr Opin Lipidol | Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of 'systemic steatosis'. | 2004 | Details |
| A53103 | 14577612 | Mol Cell Biochem | Effects of niacin-bound chromium, Maitake mushroom fraction SX and (-)-hydroxycitric acid on the metabolic syndrome in aged diabetic Zucker fatty rats. | 2003 | Details |